Abbott Laboratories (ABT) released its Q2 2025 financial results before the market opened.
Revenue for the quarter came in at $11.14 billion, surpassing estimates of $11.07 billion. Adjusted earnings were reported at $1.26 per share, slightly above the estimated $1.25.
Compared to the same quarter last year, revenue rose by approximately 7.3%, increasing from $10.38 billion and earnings grew by about 10.5%, up from $1.14 per share a year ago.
The company revised its full-year 2025 earnings outlook to a range of $5.10 to $5.20, slightly adjusting from the prior $5.05 to $5.25 estimate, while the consensus estimate stands at $5.16.
For Q3 2025, the earnings outlook is set between $1.28 and $1.32 per share, below the estimated $1.34.
Earnings Insight
| Date | Time | Symbol | company_name | Period | Metric | Estimate | Actual | Surprise | YrAgo | Growth | sector_industry |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 07/17/2025 | BMO | ABT | Abbott Laboratories | Q2 2025 | EPS | 1.25 | 1.26 | 0.80 | 1.14 | 10.50 | Healthcare / Medical Devices |
| 04/16/2025 | BMO | ABT | Abbott Laboratories | Q1 2025 | EPS | 1.07 | 1.09 | 1.87 | 0.98 | 11.20 | Healthcare / Medical Devices |
| 01/22/2025 | BMO | ABT | Abbott Laboratories | Q4 2024 | EPS | 1.07 | 1.34 | 25.23 | 1.19 | 12.60 | Healthcare / Medical Devices |
| 10/16/2024 | BMO | ABT | Abbott Laboratories | Q3 2024 | EPS | 1.20 | 1.21 | 0.83 | 1.14 | 6.10 | Healthcare / Medical Devices |
| 07/18/2024 | BMO | ABT | Abbott Laboratories | Q2 2024 | EPS | 1.10 | 1.14 | 3.64 | 1.08 | 5.60 | Healthcare / Medical Devices |